AbbVieNYSE: ABBV

Investors might want to pay attention to stocks such as COP, BERY, HII, ABBV, and ASB, as these companies have recently increased their dividend payouts.

Dividend-paying stocks are tough to surpass in terms of performance. They have shown much better results compared to stocks that do not pay dividends.

Investors have reacted favorably to AbbVie's recent results due to the increase in revenue, improved earnings forecast, and raised dividend. The company has promising growth opportunities, particularly with its Parkinson's disease treatment showing encouraging trial outcomes. However, its current high price-to-earnings ratio and the recent purchase of Aliada Therapeutics could negatively impact earnings.

AbbVie Inc. (NYSE:ABBV) will hold its Q3 2024 Earnings Conference Call on October 30, 2024, at 9:00 AM ET. The call will feature company representatives, including Liz Shea, Senior Vice President of Investor Relations, and Chief Executive Officer Robert A. Michael.

ABBV's earnings and sales for the third quarter of 2024 exceeded expectations. The company has raised its earnings per share forecast due to strong sales of its immunology medications.

While AbbVie's (ABBV) revenue and earnings per share (EPS) provide insight into its performance for the quarter ending September 2024, it could be helpful to look at how these important figures stack up against Wall Street predictions and last year's results.

AbbVie (ABBV) reported quarterly earnings of $3 per share, which is higher than the Zacks Consensus Estimate of $2.92 per share. This is an increase compared to last year's earnings of $2.95 per share.

The pharmaceutical company raised its dividend by 5.8%, bringing it to $1.64 for each share.

On Wednesday, AbbVie increased its yearly profit outlook due to strong sales from its new immunology medications and an important cancer treatment, which allowed the company to surpass Wall Street's expectations for its third-quarter earnings.